References
- Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589–600
- Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: A severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002;100:710–713
- Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: The role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001;14:437–454
- George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010;116:4060–4069
- Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043–4049
- Rossi FC, Angerami RN, de Paula EV, Orsi FL, Shang D, del Guercio VM, Resende MR, Annichino-Bizzacchi JM, da Silva LJ, Zheng XL, Castro V. A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection. Transfusion 2010;50:208–212
- Talat N, Schulte KM. Castleman's disease: Systematic analysis of 416 patients from the literature. Oncologist 2011;16:1316–1324
- Tajima K, Yamamoto H, Suzuki I, Kato Y, Hatano K, Takahashi S, et al. Autoimmune hemolytic anemia with warm-reactive immunoglobulin M antibody in multicentric Castleman disease. Ann Hematol 2013;92:849–851
- Gakiopoulou H, Korkolopoulou P, Paraskevakou H, Marinaki S, Voulgarelis M, Stofas A, et al. Membranoproliferative glomerulonephritis in the setting of multicentric angiofollicular lymph node hyperplasia (Castleman's disease) complicated by Evan's syndrome. J Clin Pathol 2010;63:552–554
- Muskardin TW, Peterson BA, Molitor JA. Castleman disease and associated autoimmune disease. Curr Opin Rheumatol 2012;24:76–83
- Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: All patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005;3:1432–1436
- Moake J. Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol 2009;22:567–576
- Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010;115:1500–1511 (quiz 662)
- Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008;3:249–277
- Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: Clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 2012;91:195–205
- Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist 2007;12:11–19
- Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012;158:323–335
- Kremer Hovinga JA, Lammle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. ASH Education Book 2012; 1:610–616
- Kawano N, Yokota-Ikeda N, Yoshida S, Kuriyama T, Yamashita K, Sugio Y, et al. Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011. Intern Med 2013;52:1883–1891